BERKELEY, Calif.--(DSM Biomedical, a global leader in biomedical materials science, and its Berkeley based operation, DSM PTG, today announced the Company will both exhibit and present at the upcoming Medical Design and Manufacturing East Conference & Exposition (MD&M East) held June 7 – 10, 2010 at the Jacob K. Javits Convention Center in New York City.)--
“Our well-established, vertically integrated approach to device development, backed up by DSM’s extensive capabilities in specialty materials manufacturing and testing is unique in our industry. This depth and our program of continual improvement and technology development enable us to stay in the forefront of biomaterials technology.”
During his June 9th presentations, CEO and President of DSM PTG, Bob Ward, will lead a session discussing exciting applications under contract development by DSM that use biomaterials in a new role – the treatment and prevention of infectious diseases. He will also participate in an expert panel addressing his experience and the challenges of using new materials in medical devices.
“With extensive experience in both biomaterials and medical devices, DSM Biomedical is a leader in bringing new polymers and specialty chemicals to material-intensive medical applications.” said Bob Ward. “Our well-established, vertically integrated approach to device development, backed up by DSM’s extensive capabilities in specialty materials manufacturing and testing is unique in our industry. This depth and our program of continual improvement and technology development enable us to stay in the forefront of biomaterials technology.”
To learn more about DSM Biomedical’s product portfolio and technologies, please visit Booth #741 at MD&M East 2010. For more information about the conference, or to register to attend, go to http://www.canontradeshows.com/expo/east10/.
About DSM Biomedical
DSM Biomedical develops novel materials-based solutions to meet the present and future needs of the medical device and biopharmaceutical industries. Building on the expertise and strengths of DSM and its acquisition of The Polymer Technology Group, which is now known as DSM PTG, the company’s product portfolio includes coatings, drug delivery platforms and a wide range of biomedical materials for use in short- and long-term implantable medical devices. Key product brands include Bionate® PCU and CarboSil® TSPCU, two of the most extensively tested biomedical polymers ever developed. Both polymers have excellent biostability, high strength and abrasion resistance, making them candidate materials for load-bearing orthopedic implants. ComfortCoat® hydrophilic and antimicrobial coating technology for catheters, guidewires and stent delivery systems; and Dyneema Purity®, a high-performance polyethylene fiber technology developed specifically for use in medical applications, such as orthopedic implants. The company also markets the Trancerta™ family of bioresorbable materials for drug delivery. This portfolio is based on DSM’s core strengths in materials science combined with its extensive in-house library of synthesis methods, formulation and processing techniques. For more information, visit www.dsmbiomedical.com.
DSM – the Life Sciences and Materials Sciences Company
Royal DSM N.V. creates solutions that nourish, protect and improve performance. Its end markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrical and electronics, life protection and housing. DSM manages its business with a focus on the triple bottom line of economic prosperity, environmental quality and social equity, which it pursues simultaneously and in parallel. DSM has annual net sales of about €8 billion and employs some 22,700 people worldwide. The company is headquartered in the Netherlands, with locations on five continents. DSM is listed on Euronext Amsterdam.